DICE Therapeutics, Inc.
DICE · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $28 | $24 | $20 | $15 |
| G&A Expenses | $11 | $8 | $6 | $6 |
| SG&A Expenses | $11 | $8 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $39 | $32 | $26 | $21 |
| Operating Income | -$39 | -$32 | -$26 | -$21 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5 | $6 | $3 | $1 |
| Pre-Tax Income | -$35 | -$26 | -$23 | -$21 |
| Tax Expense | $0 | -$6 | -$1 | -$1 |
| Net Income | -$35 | -$20 | -$23 | -$20 |
| % Margin | – | – | – | – |
| EPS | -0.74 | -0.42 | -0.5 | -0.53 |
| % Growth | -76.2% | 16% | 5.7% | – |
| EPS Diluted | -0.74 | -0.42 | -0.5 | -0.53 |
| Weighted Avg Shares Out | 47 | 47 | 45 | 37 |
| Weighted Avg Shares Out Dil | 47 | 47 | 45 | 37 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $6 | $4 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $6 | $4 | $1 |
| EBITDA | -$34 | -$26 | -$19 | -$20 |
| % Margin | – | – | – | – |